Modifying Clinical Studies Midstream Can Be Done, With Caution, FDA Says
This article was originally published in The Gray Sheet
Adaptive device clinical trials, where study is designed in anticipation of midstream changes, are the focus on a new FDA draft guidance. Adaptive trials can reduce the duration and cost of a study without undermining its integrity, but the practice should be applied with caution, FDA says.
You may also be interested in...
A newly finalized guidance document offers the US agency’s take on how and when clinical trials can be modified midstream. It includes some revisions from a draft version, including more attention paid the possibility of adaptive single-arm trials.
An FDA Science Board subcommittee report finds industry and researcher perceptions of FDA's science readiness has improved over the past eight years. But the agency still faces major challenges tied to the current speed of scientific and technical progress.
Basket trials like NCI-MATCH could show the value of adaptive clinical trial designs based on advanced Bayesian statistics, furthering a goal of the 21st Century Cures draft legislation.